An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Sage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Sage Therapeutics, Inc. (Nasdaq: SAGE) will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1 at 8:30am ET. Investors can access the live webcast via Sage's Investor page. A replay will be made available approximately two hours following the event and archived for up to 30 days. Sage focuses on developing innovative therapies aimed at transforming the lives of individuals with debilitating brain disorders, including programs in depression and neurology.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1 at 8:30am ET.
A live webcast of the fireside chat can be accessed on the Investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
